Ikena Oncology Inc (NAS:IKNA)
$ 1.735 -0.115 (-6.22%) Market Cap: 83.73 Mil Enterprise Value: -47.05 Mil PE Ratio: 0 PB Ratio: 0.63 GF Score: 30/100

Ikena Oncology Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 14, 2022 / 03:45PM GMT
Release Date Price: $4.72 (-5.79%)
Unidentified Analyst

Thank you for coming to the Ikena fireside chat. My name is Albert Wong with Morgan Stanley. For research disclosure, I'm going to read a statement here. For important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

So I have with me Mark Manfredi, who is the CEO. Mark, if you could please introduce yourself and maybe give a quick 3-minute overview on the company before we get started.

Mark Manfredi
Ikena Oncology, Inc. - President. CEO & Director

Sure. Sure. So I'm Mark Manfredi, CEO of Ikena. Been with the company for 6.5 years, which is since the inception of the company. Scientist by training. I spent most of my career at Millennium Pharmaceuticals and then Takeda with the acquisition that was about 14 years total, all in R&D Oncology. And from there went off to Atlas Venture to work on oncology newcos and started up Ikena from there.

And so the company started in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot